February 08, 2025 — 08:30 am EST
Written by for The Motley Fool->
Dividend stocks are great for many reasons, not least because any company that can sustain growing payouts for a long time likely has a strong underlying business. It's even better to invest in excellent income stocks when they seem to be trading at attractive valuations, which isn't always easy to find since such corporations are in high demand.
Thankfully, there are such stocks on the market, and below are two examples: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). Here's the rundown.
The past couple of years have been tumultuous for AbbVie. The company lost patent exclusivity for its best-selling drug, Humira, in early 2023, initially leading to a massive drop in revenue, earnings, and share price. While it had managed to rebound from that setback, AbbVie's shares fell off a cliff late last year when one of its exciting pipeline candidates, emraclidine (a potential schizophrenia medicine), failed phase 2 studies.
The drugmaker has also recouped much of the losses from that debacle, but its shares remain fairly valued, at least according to one of the most popular valuation ratios on the market. The company's forward price-to-earnings (P/E) ratio stands at 15.5, compared to the healthcare industry's average of 17.5. AbbVie looks attractive at current levels, given its prospects and excellent dividend program. Here's why. Despite losing patent exclusivity for one of the most lucrative drugs ever, AbbVie's top line is moving in the right direction.
The company's revenue in 2024 increased by 3.7% to $56.3 billion. AbbVie's adjusted earnings per share for the year decreased by 9% year over year to $10.12, although that was partly because of acquisition-related expenses. Replacing a drug that generated more than $20 billion in annual sales at its peak is not easy, so the fact that AbbVie's revenue is growing at all is impressive. The company's setback with emraclidine isn't the end of the world either. AbbVie's pipeline features dozens of programs, and the company has the means to strike deals with other (smaller) drugmakers to replenish its lineup.
AbbVie's underlying business remains strong, and so does its dividend program. The company is a Dividend King with 52 consecutive years of dividend increases under its belt. It also offers a forward yield of about 3.7%. Income investors can't go wrong with this stock.
Gilead Sciences has performed well in the trailing-12-month period. The company's shares are up by almost 29%. Still, the drugmaker's shares look like a bargain, given its forward P/E of 12.9. Gilead Sciences has several things going its way beyond its valuation. The company's lineup of medicines, led by its HIV products, continues to perform well. In the first nine months of 2024, Gilead's revenue increased by a respectable 6% year over year to $21.2 billion.
The company reported adjusted EPS of $2.72 in the period, down almost 46% compared to the third period of the previous fiscal year, but like with AbbVie, that was largely due to charges related to acquisitions. Gilead's HIV regimen, Biktarvy, remains the leader in the U.S., and once again grew its market share, which now stands at more than 49%. Further, Gilead Sciences has substantially decreased its reliance on its coronavirus medicine, Veklury, which significantly helped keep its sales afloat in the early pandemic years.
And regarding its pipeline, Gilead Sciences is making progress on multiple fronts. The company is developing medicines across various therapeutic areas, including HIV, immunology, and oncology. Gilead Sciences has ramped up its oncology-related efforts in the past few years. It is running more than two dozen clinical trials in this area, many of which are phase 3 studies. Some of Gilead Sciences' existing products, such as long-acting HIV medicine Sunlenca, will earn label expansions in the future.
So, Gilead Sciences' financial results should remain strong. Meanwhile, the drugmaker has increased its dividend by about 79% in the past 10 years, and its forward yield is about 3.1%. This dividend stock is an excellent pick for long-term income-seeking investors, especially at current levels.
Here is the link.
#PhasesOfTrading #LosingMoney #ProfitableTrader #UnprofitableTrader #ReasonsLosing #JuliaPhase1 #JuliaUnprofitable #JuliaStrategy #SmallWins #LargerLosses
Boom-and-Bust trader
Characteristics
Here is the link.
Access the presentations of all 16 experts from the 2021 TraderLion Conference. Learn from top traders, hedge fund managers, trading psychologists, and more - https://traderlion.com/YT_TLC21 In this video, Charles Harris, Portfolio Manager at O'Neil Capital Management walks through his process of How to buy pullbacks. Buying pullbacks is an excellent technique when looking for alternative buy points and can provide excellent low-risk entries into leading names when done correctly. Charles provides an amazing crash course into his pullback strategy and techniques and how to buy the dip correctly. 00:00:00 - Introduction How to Trade Pullbacks 00:06:28 - General Pullback Rules 00:10:48 - O'Neil's Approach to Buying/Adding 00:11:10 - Chart Examples 00:16:26 - Upside Reversal Day 00:26:14 - Defining Your Risk 00:50:50 - 3 Techniques for Buying Weakness 01:00:49 - Conclusion 01:02:31 - Q&A
Conclusion
Buying pullbacks in conjunction with buying breakouts can improve your overall results
Here is the link.
BigBear.ai (BBAI) stock plummeted by 18% on Wednesday, January 8, 2025, due to two main factors. First, reports emerged that President-elect Trump might declare a national economic emergency to rapidly implement wide-ranging tariffs on foreign goods, causing market-wide concern and particularly affecting high-risk stocks with speculative outlooks. Second, Deutsche Bank reaffirmed its sell rating on Palantir Technologies, a company often compared to BigBear.ai in the AI and defense contracting space. Although Deutsche Bank raised its price target for Palantir, it still suggested a significant downside, indirectly impacting BigBear.ai's stock. The company's uncertain path to profitability, despite its recent sales momentum, contributed to investor caution in light of these developments
Here is the link.
Here is the link.
Here is the link.
Here is the link.
D W M charts
Here is the link.
